Refine
Year of publication
Document Type
- Article (48)
- Preprint (7)
- Working Paper (1)
Has Fulltext
- yes (56)
Is part of the Bibliography
- no (56)
Keywords
- ADHD (6)
- bipolar disorder (4)
- Bipolar disorder (3)
- Aspergillus fumigatus (2)
- COVID-19 (2)
- Genetics (2)
- attention (2)
- continuous performance test (2)
- hyperactivity (2)
- impulsivity (2)
- polygenic risk score (2)
- 16p11.2 (1)
- 2030 Agenda (1)
- ADHD differential diagnosis (1)
- AML (1)
- ARDS (1)
- Accidents (1)
- Affective disorders (1)
- Amphetamine (1)
- Atomoxetine (1)
- Attention (1)
- Autism (1)
- Biodiversity (1)
- Biomarker (1)
- CRISPR/Cas9 (1)
- CVID (1)
- Cognitive dysfunction (1)
- Consensus (1)
- Conservation biology (1)
- Critical care (1)
- Depression (1)
- Diagnostic markers (1)
- Diagnostic test (1)
- Differential diagnosis (1)
- EBM (1)
- Electron-pion identification (1)
- Environmental impact (1)
- European Society for Immunodeficiencies (ESID) (1)
- Evidence-based (1)
- Evidenzbasierung (1)
- Fibre/foam sandwich radiator (1)
- GHQ-28 (1)
- Genome-wide association studies (1)
- German PID-NET registry (1)
- Guidelines (1)
- HDAC (1)
- HDACi (1)
- Heuristic (1)
- IgG substitution therapy (1)
- Immune response (1)
- Immunity (1)
- Immunogenetics (1)
- Immunology (1)
- Immunology and Microbiology Section (1)
- Injuries (1)
- Ionisation energy loss (1)
- Konsens (1)
- Kynurenine (1)
- Leitlinien (1)
- Lithium (1)
- MYC (1)
- Maintenance treatment (1)
- Mania (1)
- Methylphenidate (1)
- Monitoring (1)
- Multi-wire proportional drift chamber (1)
- Multiplex immunoassay (1)
- Nesplora Aquarium (1)
- Neural network (1)
- Non-linear cost (1)
- Normative dimension (1)
- Outcome (1)
- PARK2 (1)
- PCR (1)
- PID prevalence (1)
- Pandemic (1)
- Polarity index (1)
- Postvention (1)
- Predominant polarity (1)
- Prize-collecting (1)
- Prognostic models (1)
- Psychiatric disorders (1)
- Qb-Test (1)
- QbTest® (1)
- Quinolinate phosphoribosyltransferase (1)
- Quinolinic acid (1)
- Randomized controlled trial (1)
- Renal replacement therapy (1)
- SARS-CoV-2 (1)
- Schizophrenia (1)
- Science–society interactions (1)
- Sholl analysis (1)
- Stimulant (1)
- Suicidal behavior (1)
- Suicidal thoughts (1)
- Suicidality (1)
- Suicide (1)
- Suizidalität (1)
- Sustainability research (1)
- TR (1)
- Tracking (1)
- Trajectories (1)
- Transition radiation detector (1)
- Trigger (1)
- UPPS (1)
- Vehicle routing (1)
- Viral infection (1)
- WT1 (1)
- Working memory capacity (1)
- Xenon-based gas mixture (1)
- accidents (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- affective disorder (1)
- affective disorders (1)
- anaesthesia in orthopaedics (1)
- anaesthetics (1)
- antisynthetase antibodies (1)
- antisynthetase syndrome (1)
- arthritis (1)
- attention deficit hyperactivity disorder (1)
- attention-deficit/hyperactivity disorder (1)
- biomarker (1)
- blood (1)
- body mass index (1)
- ceramides (1)
- cholangiocarcinoma (1)
- common variant (1)
- cross-sectional study (1)
- cytokine (1)
- dE/dx (1)
- depression (1)
- diabetes mellitus (1)
- disease modelling (1)
- early recognition (1)
- ectosomes (1)
- endocannabinoids (1)
- epigenetics (1)
- ex-Gaussian analysis (1)
- exosomes (1)
- extracellular vesicles (1)
- gene expression (1)
- genetic phenotypes (1)
- gene×environment interactions (1)
- geriatric medicine (1)
- glucose metabolism (1)
- guidelines (1)
- hematopoietic stem cell transplantation (1)
- hiPSC (1)
- human natural killer cell (1)
- immunohistochemistry (1)
- immunotherapy (1)
- indomethacin (1)
- interoperability (1)
- interstitial lung disease (1)
- machine learning (1)
- major depression (1)
- major depression (MD) (1)
- major depressive disorder (MDD) (1)
- mesenchymal stromal cells (1)
- metabolic syndrome (1)
- microparticles (1)
- microsatellite instability (1)
- microvesicles (1)
- minimal information requirements (1)
- mitochondria (1)
- molecular marker (1)
- myositis (1)
- naturalistic sample (1)
- neuropsychology (1)
- obesity (1)
- perforin (1)
- phagocytosis (1)
- pharmacogenetics (1)
- prediabetes (1)
- primary immunodeficiency (PID) (1)
- proteome (1)
- psychosocial stress (1)
- rare variant (1)
- registry for primary immunodeficiency (1)
- reproducibility (1)
- rigor (1)
- risk genes (1)
- smart home (1)
- smart living (1)
- standardization (1)
- substance abuse disorder (1)
- tandem mass spectrometry (1)
- venturesomeness (1)
- web of things (1)
- β-catenin (1)
Institute
While impulsivity is a basic feature of attention-deficit / hyperactivity disorder (ADHD), no study explored the effect of different components of the Impulsiveness (Imp) and Venturesomeness (Vent) scale (IV7) on psychiatric comorbidities and an ADHD polygenic risk score (PRS). We used the IV7 self-report scale in an adult ADHD sample of 903 patients, 70% suffering from additional comorbid disorders, and in a subsample of 435 genotyped patients. Venturesomeness, unlike immediate Impulsivity, is not specific to ADHD. We consequently analyzed the influence of Imp and Vent also in the context of a PRS on psychiatric comorbidities of ADHD. Vent shows a distinctly different distribution of comorbidities, e.g., less anxiety and depression. PRS showed no effect on different ADHD comorbidities, but correlated with childhood hyperactivity. In a complementary analysis using principal component analysis with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition ADHD criteria, revised NEO Personality Inventory, Imp, Vent, and PRS, we identified three ADHD subtypes. These are an impulsive–neurotic type, an adventurous–hyperactive type with a stronger genetic component, and an anxious–inattentive type. Our study thus suggests the importance of adventurousness and the differential consideration of impulsivity in ADHD. The genetic risk is distributed differently between these subtypes, which underlines the importance of clinically motivated subtyping. Impulsivity subtyping might give insights into the organization of comorbid disorders in ADHD and different genetic background.
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1–25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous; 29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
The three-dimensional quantification of small scale processes in the upper troposphere and lower stratosphere is one of the challenges of current atmospheric research and requires the development of new measurement strategies. This work presents first results from the newly developed Gimballed Limb Observer for Radiance Imaging of the Atmosphere (GLORIA) obtained during the ESSenCe and TACTS/ESMVal aircraft campaigns. The focus of this work is on the so-called dynamics mode data characterized by a medium spectral and a very high spatial resolution. The retrieval strategy for the derivation of two- and three-dimensional constituent fields in the upper troposphere and lower stratosphere is presented. Uncertainties of the main retrieval targets (temperature, O3, HNO3 and CFC-12) and their spatial resolution are discussed. During ESSenCe, high resolution two-dimensional cross-sections have been obtained. Comparisons to collocated remote-sensing and in-situ data indicate a good agreement between the data sets. During TACTS/ESMVal a tomographic flight pattern to sense an intrusion of stratospheric air deep into the troposphere has been performed. This filament could be reconstructed with an unprecedented spatial resolution of better than 500 m vertically and 20 km × 20 km horizontally.
The three-dimensional quantification of small-scale processes in the upper troposphere and lower stratosphere is one of the challenges of current atmospheric research and requires the development of new measurement strategies. This work presents the first results from the newly developed Gimballed Limb Observer for Radiance Imaging of the Atmosphere (GLORIA) obtained during the ESSenCe (ESa Sounder Campaign) and TACTS/ESMVal (TACTS: Transport and composition in the upper troposphere/lowermost stratosphere, ESMVal: Earth System Model Validation) aircraft campaigns. The focus of this work is on the so-called dynamics-mode data characterized by a medium-spectral and a very-high-spatial resolution. The retrieval strategy for the derivation of two- and three-dimensional constituent fields in the upper troposphere and lower stratosphere is presented. Uncertainties of the main retrieval targets (temperature, O3, HNO3, and CFC-12) and their spatial resolution are discussed. During ESSenCe, high-resolution two-dimensional cross-sections have been obtained. Comparisons to collocated remote-sensing and in situ data indicate a good agreement between the data sets. During TACTS/ESMVal, a tomographic flight pattern to sense an intrusion of stratospheric air deep into the troposphere was performed. It was possible to reconstruct this filament at an unprecedented spatial resolution of better than 500 m vertically and 20 × 20 km horizontally.
Immune-modulating therapy is a promising therapy for patients with cholangiocarcinoma (CCA). Microsatellite instability (MSI) might be a favorable predictor for treatment response, but comprehensive data on the prevalence of MSI in CCA are missing. The aim of the current study was to determine the prevalence of MSI in a German tertiary care hospital. Formalin-fixed paraffin-embedded tissue samples, obtained in the study period from 2007 to 2015 from patients with CCA undergoing surgical resection with curative intention at Johann Wolfgang Goethe University hospital, were examined. All samples were investigated immunohistochemically for the presence of MSI (expression of MLH1, PMS2, MSH2, and MSH6) as well as by pentaplex polymerase chain reaction for five quasimonomorphic mononucleotide repeats (BAT-25, BAT-26, NR-21, NR-22, and NR-24). In total, 102 patients were included, presenting intrahepatic (n = 35, 34.3%), perihilar (n = 42, 41.2%), and distal CCA (n = 25, 24.5%). In the immunohistochemical analysis, no loss of expression of DNA repair enzymes was observed. In the PCR-based analysis, one out of 102 patients was found to be MSI-high and one out of 102 was found to be MSI-low. Thus, MSI seems to appear rarely in CCA in Germany. This should be considered when planning immune-modulating therapy trials for patients with CCA.
Exported proteases of Helicobacter pylori (H. pylori) are potentially involved in pathogen-associated disorders leading to gastric inflammation and neoplasia. By comprehensive sequence screening of the H. pylori proteome for predicted secreted proteases, we retrieved several candidate genes. We detected caseinolytic activities of several such proteases, which are released independently from the H. pylori type IV secretion system encoded by the cag pathogenicity island (cagPAI). Among these, we found the predicted serine protease HtrA (Hp1019), which was previously identified in the bacterial secretome of H. pylori. Importantly, we further found that the H. pylori genes hp1018 and hp1019 represent a single gene likely coding for an exported protein. Here, we directly verified proteolytic activity of HtrA in vitro and identified the HtrA protease in zymograms by mass spectrometry. Overexpressed and purified HtrA exhibited pronounced proteolytic activity, which is inactivated after mutation of Ser205 to alanine in the predicted active center of HtrA. These data demonstrate that H. pylori secretes HtrA as an active protease, which might represent a novel candidate target for therapeutic intervention strategies.
The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field in 2014. We now update these “MISEV2014” guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV-associated functional activities. Finally, a checklist is provided with summaries of key points.
Studies have demonstrated an increased risk of accidents and injuries in children, adolescents and adults with attention-deficit/hyperactivity disorder (ADHD). However, little is known about how accident risk may alter over the lifespan. Additionally, it would be important to know if the most common types of accidents and injuries differ in ADHD patients over different age groups. Furthermore, there is increasing evidence of an ameliorating effect of ADHD medication on accident risk. Lastly, the underlying risk factors and causal mechanisms behind increased accident risk remain unclear. We therefore conducted a systematic review focusing on the above described research questions. Our results suggested that accident/injury type and overall risk changes in ADHD patients over the lifespan. ADHD medication appeared to be similarly effective at reducing accident risk in all age groups. However, studies with direct comparisons of accident/injuries and effects of medication at different age groups or in old age are still missing. Finally, comorbidities associated with ADHD such as substance abuse appear to further increase the accident/injury risk.
Transdiagnostic comparison of visual working memory capacity in bipolar disorder and schizophrenia
(2021)
Background: Impaired working memory is a core cognitive deficit in both bipolar disorder and schizophrenia. Its study might yield crucial insights into the underpinnings of both disorders on the cognitive and neurophysiological level. Visual working memory capacity is a particularly promising construct for such translational studies. However, it has not yet been investigated across the full spectrum of both disorders. The aim of our study was to compare the degree of reductions of visual working memory capacity in patients with bipolar disorder (PBD) and patients with schizophrenia (PSZ) using a paradigm well established in cognitive neuroscience.
Methods: 62 PBD, 64 PSZ, and 70 healthy controls (HC) completed a canonical visual change detection task. Participants had to encode the color of four circles and indicate after a short delay whether the color of one of the circles had changed or not. We estimated working memory capacity using Pashler’s K.
Results: Working memory capacity was significantly reduced in both PBD and PSZ compared to HC. We observed a small effect size (r = .202) for the difference between HC and PBD and a medium effect size (r = .370) for the difference between HC and PSZ. Working memory capacity in PSZ was also significantly reduced compared to PBD with a small effect size (r = .201). Thus, PBD showed an intermediate level of impairment.
Conclusions: These findings provide evidence for a gradient of reduced working memory capacity in bipolar disorder and schizophrenia, with PSZ showing the strongest degree of impairment. This underscores the importance of disturbed information processing for both bipolar disorder and schizophrenia. Our results are compatible with the cognitive manifestation of a neurodevelopmental gradient affecting bipolar disorder to a lesser degree than schizophrenia. They also highlight the relevance of visual working memory capacity for the development of both behavior- and brain-based transdiagnostic biomarkers.
Highlights
• A panel of 20 biomarkers was identified capable of differentiating BD patients from controls.
• Excellent discrimination between established BD patients and controls.
• Good to excellent discrimination between misdiagnosed BD patients and first onset MDD patients.
• Fair to good discrimination between pre-diagnostic BD patients and controls.
• Study demonstrates the potential utility of a protein biomarker panel as a diagnostic test for BD.
Abstract
Background: Bipolar disorder (BD) is a costly, devastating and life shortening mental disorder that is often misdiagnosed, especially on initial presentation. Misdiagnosis frequently results in ineffective treatment. We investigated the utility of a biomarker panel as a diagnostic test for BD.
Methods and findings: We performed a meta-analysis of eight case-control studies to define a diagnostic biomarker panel for BD. After validating the panel on established BD patients, we applied it to undiagnosed BD patients. We analysed 249 BD, 122 pre-diagnostic BD, 75 pre-diagnostic schizophrenia and 90 first onset major depression disorder (MDD) patients and 371 controls. The biomarker panel was identified using ten-fold cross-validation with lasso regression applied to the 87 analytes available across the meta-analysis studies.
We identified 20 protein analytes with excellent predictive performance [area under the curve (AUC) ⩾ 0.90]. Importantly, the panel had a good predictive performance (AUC 0.84) to differentiate 12 misdiagnosed BD patients from 90 first onset MDD patients, and a fair to good predictive performance (AUC 0.79) to differentiate between 110 pre-diagnostic BD patients and 184 controls. We also demonstrated the disease specificity of the panel.
Conclusions: An early and accurate diagnosis has the potential to delay or even prevent the onset of BD. This study demonstrates the potential utility of a biomarker panel as a diagnostic test for BD.